Core Viewpoint - The company, 佛慈制药, is focusing on expanding its international presence by leveraging its export advantages and increasing investments in overseas operations [1] Group 1: International Expansion - The company's products have been exported to 32 countries and regions [1] - The number of overseas product registrations has reached 1,442, indicating a strong foothold in international markets [1] - The company maintains a leading position in the industry regarding the number of foreign certifications, overseas trademark registrations, and the range of exported products [1] Group 2: Strategic Initiatives - The company plans to deepen its international strategic layout by enhancing overseas construction investments [1] - Efforts will be made to promote international product registration and compliance certification [1] - The company aims to strengthen promotion through brand co-construction and channel sharing to continuously expand its overseas market share [1]

Core Viewpoint - The company aims to strengthen its domestic market sales while actively developing potential markets by implementing differentiated product sales strategies and leveraging e-commerce platforms like JD and Tmall to enhance market share [1] Group 1: Sales Strategy - The company plans to consolidate its existing domestic market sales while exploring new potential markets in the first half of 2025 [1] - A systematic review of different channels and key customers will be conducted to formulate differentiated product sales policies [1] - The integration of online and offline sales through e-commerce platforms is a key focus to boost product market share [1] Group 2: Sales Channel Distribution - Currently, over 60% of sales come from commercial chain channels, approximately 20% from medical channels, and around 20% from online, agency, and other channels [1] - Overall sales performance across all channels has shown little change compared to the same period last year [1]